Acarbose
- Generic Name
- Acarbose
- Brand Names
- Precose
- Drug Type
- Small Molecule
- Chemical Formula
- C25H43NO18
- CAS Number
- 56180-94-0
- Unique Ingredient Identifier
- T58MSI464G
- Background
Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are responsible for the metabolism of complex starches and oligo-, tri-, and disaccharides into absorbable simple sugars. By inhibiting the activity of these enzymes, acarbose limits the absorption of dietary carbohydrates and the subsequent postprandial increase in blood glucose and insulin levels. Acarbose is therefore used in conjunction with diet, exercise, and other pharmacotherapies for the management of blood sugar levels in patients with type 2 diabetes.
Acarbose is one of only two approved alpha-glucosidase inhibitors (the other being miglitol), receiving its first FDA approval in 1995 under the brand name Precose (since discontinued). This class of antidiabetic therapy is not widely used due to their relatively modest impact on A1c, their requirement for thrice-daily dosing, and the potential for significant gastrointestinal adverse effects.
- Indication
Acarbose is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-11-16
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
- Target Recruit Count
- 100
- Registration Number
- NCT02605772
Human Oral Detection of Glucose Olygomers
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Oregon State University
- Target Recruit Count
- 157
- Registration Number
- NCT02589353
- Locations
- 🇺🇸
Department of Food Science and Technology, Corvallis, Oregon, United States
Treatment of Hypoglycemia Following Gastric Bypass Surgery
- Conditions
- HypoglycemiaObesitySurgery
- Interventions
- Device: Continuous glucose monitoring (CGM)Dietary Supplement: Meal tolerance test (MTT)
- First Posted Date
- 2015-08-19
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- Zealand University Hospital
- Target Recruit Count
- 11
- Registration Number
- NCT02527993
Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM Patients
- Conditions
- Type 2 DiabetesGemigliptinAcarboseEndothelial Function
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 54
- Registration Number
- NCT02500329
- Locations
- 🇰🇷
Boramae medical center, Seoul, Korea, Republic of
Research of Intensive Lifestyle Intervention for PCOS Patients With IGT
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- Behavioral: intensive lifestyle intervention
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT02446834
- Locations
- 🇨🇳
Renji Hospital Department of Endocrinology and Metabolism, Shanghai, Shanghai, China
the Efficacy of Acarbose and Metformin on Blood Glucose Fluctuation When Combined With Premix Insulin
- First Posted Date
- 2015-05-08
- Last Posted Date
- 2015-05-08
- Lead Sponsor
- Shanghai 6th People's Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT02438397
- Locations
- 🇨🇳
the 6th affliliated hospital of Shanghai Jiaotong university, Shanghai, Shanghai, China
Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients
- Conditions
- Glucose IntolerancePostprandial HyperglycemiaCardiovascular Risk Factor
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-02-04
- Last Posted Date
- 2015-02-09
- Lead Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Target Recruit Count
- 21
- Registration Number
- NCT02355509
- Locations
- 🇲🇽
Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, México City, Distrito Federal, Mexico
Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes
- First Posted Date
- 2014-12-12
- Last Posted Date
- 2018-07-06
- Lead Sponsor
- Zilin Sun
- Target Recruit Count
- 22
- Registration Number
- NCT02315495
- Locations
- 🇨🇳
Department of Endocrinology, Zhongda Hospital. Institute of Diabetes, Southeast University, Nanjing, Jiangsu, China
24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2017-04-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 689
- Registration Number
- NCT02243176
- Locations
- 🇨🇳
Research Site, Shanghai, China
Relative Bioavailability of BI 44847 in Different Ethnic Groups and Evaluation of Effect of Diet and Acarbose Coadministration on Bioavailability Following Oral Administration of 200 mg BI 44847 in Healthy Male Volunteers
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2014-08-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 37
- Registration Number
- NCT02211950
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.